AMEX · ATNM
Healthcare · Biotechnology
$1.10
Down-$0.02 (-1.79%)
Updated Aug 23, 2026, 10:39 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ATNM closed at $1.10 after 20 trading sessions, up 28.75% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.13 | $1.14 | $1.10 | $1.10 | 144.01K |
| Aug 20, 2026 | $1.13 | $1.14 | $1.07 | $1.12 | 121.42K |
| Aug 19, 2026 | $1.09 | $1.15 | $1.05 | $1.13 | 183.41K |
| Aug 18, 2026 | $1.05 | $1.115 | $1.03 | $1.08 | 211.2K |
| Aug 17, 2026 | $1.11 | $1.13 | $1.05 | $1.05 | 344.94K |
| Aug 14, 2026 | $0.95 | $1.09 | $0.9351 | $1.04 | 490.51K |
| Aug 13, 2026 | $0.849 | $0.98 | $0.8451 | $0.9639 | 284.68K |
| Aug 12, 2026 | $0.80 | $0.829 | $0.79 | $0.8211 | 240.65K |
| Aug 11, 2026 | $0.78 | $0.8241 | $0.7701 | $0.7931 | 168.77K |
| Aug 10, 2026 | $0.80 | $0.808 | $0.76 | $0.7702 | 177.3K |
| Aug 7, 2026 | $0.79 | $0.80 | $0.772 | $0.7974 | 133.32K |
| Aug 6, 2026 | $0.75 | $0.7885 | $0.7474 | $0.787 | 98.94K |
| Aug 5, 2026 | $0.80 | $0.8051 | $0.7351 | $0.7487 | 349.56K |
| Aug 4, 2026 | $0.811 | $0.83 | $0.81 | $0.81 | 92.12K |
| Aug 3, 2026 | $0.8369 | $0.8619 | $0.81 | $0.8115 | 200.15K |
| Jul 31, 2026 | $0.8369 | $0.85 | $0.8369 | $0.8369 | 35.41K |
| Jul 30, 2026 | $0.8369 | $0.8499 | $0.8369 | $0.837 | 26.32K |
| Jul 29, 2026 | $0.85 | $0.8818 | $0.8339 | $0.8369 | 80.8K |
| Jul 28, 2026 | $0.8603 | $0.8667 | $0.845 | $0.8665 | 72.4K |
| Jul 27, 2026 | $0.88 | $0.88 | $0.8068 | $0.8544 | 123.73K |
The latest Smart Investors Daily articles mentioning ATNM.
ATNM research
Company profile and research snapshot.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 31, 2026 | Stephens & Co. | Overweight | — |
| Jun 24, 2025 | HC Wainwright & Co. | Buy | — |
| May 12, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 28, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents
Benzinga · Aug 14, 2026
American LLC ("NYSE American") that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide (the "Company
Benzinga · Aug 12, 2026
Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $(0.21) by 523.81 percent. This is a 504.55 percent increase over losses of $(0.22) per
Benzinga · Feb 17, 2026
AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology ApplicationsNEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ATNM.
